
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. has demonstrated significant growth in its operations, with total revenue for 4Q24 reaching $49.0 million, marking a 26% year-over-year increase that aligns with prior projections. The company has expanded its sales force and active surgeon count, which rose approximately 23% year-over-year to around 1,400, indicating strong demand and improved engagement in their minimally invasive surgical products. Furthermore, SI-BONE's gross margin improved to 79.1%, exceeding consensus expectations, and productivity metrics per physician also showed promising upward trends, suggesting a solid foundation for future growth.
Bears say
The analysis indicates a negative outlook for SI-BONE, driven by an assumption of weaker-than-expected revenue growth domestically and persistent challenges in international markets, with projections estimating significant underperformance in order to achieve a valuation around $13 per share. Furthermore, the company has a history of substantial financial losses, anticipated to continue in the near term, raising concerns about potential cash burn that may necessitate additional capital raises. Additional risks, including competitive pressures, patent expirations, sales execution issues, adverse market conditions, and reimbursement challenges, further contribute to the uncertainty surrounding the company's financial stability and growth trajectory.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares